GA-FINEOS-CORPORATION
24.3.2022 14:17:06 CET | Business Wire | Press release
The FINEOS Corporation (ASX:FCL ), the leading core platform for life, accident and health insurance globally, released a set of product updates within the cloud-native FINEOS Platform that provide expanded capabilities across Group, Voluntary, and Absence Management products. The updates fulfil needs throughout the full customer spectrum across insurers, employers, and employees to support sales and service effectiveness, new product speed to market, and an enriched customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005534/en/
To gain deeper insights into the FINEOS Platform Winter Release, join the live product management panel discussion: The FINEOS Platform: Purpose-Built for Innovation and Growth on April 14, 2022 at 11:30 am ET.
"This release marks another significant step forward in how the FINEOS Platform serves all parts of the Group, Voluntary, and Absence value chain. We are solving more problems for our customers and doing so in uniquely seamless ways,” said Eoin Kirwan, Chief Product Officer, FINEOS.
The FINEOS Platform Group, Voluntary, and Absence Management Enhancements Include:
Sales and Underwriting Effectiveness
- Integrated Experience Rating: NextGen functionality for the underwriting and actuarial teams to drive profitability across their book of business. Via an embedded user experience, an underwriter can leverage prior claims experience to provide the best appropriate rate for the customer while providing leading risk management principles for the insurer. The experience rate is blended with the manual rate based upon insurer rules and preferences.
- Enhanced Group Underwriting provides one view of the employer at time of quote: Integrated pricing flexibility and enhanced underwriting processes provides real time adjustment to changing market needs. Whole case underwriting enables optimized product bundles based on the employer’s total need and drives greater enrollment participation.
- LIMRA LDEx API Enhancements: Enhanced LIMRA LDEx APIs include absence management connectivity and data management.
New Product Speed to Market
- Voluntary Benefits Product Enhancements for Policy, Billing, and Claims: Enhanced claims integration and automation capabilities for accident, critical illness, and hospital indemnity enables insurers to leverage integrated eligibility and enrollment data for member elections to drive voluntary product claim acceleration and auto adjudication.
- Additional Member Management and Bill Processing: This release provides extended support for the variety of administrative models across group insurance and worksite for member management.
- Billing Enhancements: Enhanced list bill processing supports the increased consumer centric product and services required by the market with additional billing support for insured Paid Family and Medical Leave (PFML) policies.
Customer Experience
- Robust Employer Dashboard and Reporting Portal and APIs: Real-time data dashboards enable employers to view workforce leave information and review data in graphical views, filter the data by leave reason, groups, and dates. Reports can be exported in Excel or PDF formats to gain insight into individual case details.
- Intermittent Leave Process Improvement: This release reduces friction associated with intermittent leave, including surfacing the right level of information and automation, low-touch, and no-touch options, such as over-frequency tolerance rule.
- Paid Leave Integration: Enriched integration and automation between paid leave, unpaid leave, disability, and voluntary benefits that pertain to an employee’s single leave reason, reduces duplicate work and errors, and providing a single source of truth across the value chain for all elements of an employee’s leave claim.
“As the only purpose-built, cloud-native core insurance solution for the life, accident and health market, the FINEOS Platform remains ahead of the curve in meeting the technical and operational needs of insurers,” said Michael Kelly, CEO, FINEOS. “Deployable as an end-to-end core solution, or as components to enable incremental transformation efforts, the FINEOS Platform has something for the entire Employee Benefits value chain including better support for the sales/service process, the customer experience and the ability to deal with a broad range of products and services such as absence management,” added Kelly.
About FINEOS Corporation
FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest employee benefits insurers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative, progressive insurers in North America, Europe, and Asia Pacific.
The FINEOS Platform is the only purpose-built, end-to-end SaaS insurance solution for the life, accident and health market. The FINEOS AdminSuite delivers industry leading capabilities across core administration including absence management, billing, claims, payments, policy administration, provider management and new business and underwriting; all of which are configurable to operate independently or as one suite. The machine learning enabled FINEOS Engage solution enables robust people first digital engagement pathways and the FINEOS Insight solution provides predictive analytics and reporting across the business.
For more information, visit www.FINEOS.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005534/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
